InDex Gets Cash Boost For Phase III Ulcerative Colitis Drug
Swedish Firm's Cobitolimod Could Be A Blockbuster
The Stockholm-based company is in a position to start the Phase III program for its ulcerative colitis candidate after raising over $64m in a rights issue.
You may also be interested in...
Almirall has returned ulcerative colitis therapy Kappaproct to its originator company InDex Pharmaceuticals.
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
Ipsen CEO David Loew recently told Scrip that a return to more rational valuations for biotechs should led to more deals. The Epizyme acquisition could be the first of many by the French group this year.